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Figure S1. Validation of hits from epigenetic drug screen. 
(A) Tenovin-1 (p53 activator), one of the top three positive compounds from the cell-based screen 
(Figure 1A), was subjected to cell viability assay using MTS. Treatments with tenovin-1 did not 
significantly increase the viability of mutant Htt-expressing neurons (ANOVA, *P < 0.0001 compared to 
Htt-25Q (0 µM); P = 0.591, Htt-72Q (0.02 µM) vs Htt-72Q (0 µM); P = 0.355, Htt-72Q (0.2 µM) vs Htt-72Q 
(0 µM); P = 0.168, Htt-72Q (2 µM) vs Htt-72Q (0 µM); n = 6-12 wells per group).   
(B) AG-014699 (PARP1 inhibitor), another screen hit, was subjected to cell viability assay as in (A). 
There is no significant difference in survival between the AG-014699- and vehicle-treated Htt-72Q 
neurons (ANOVA, *P < 0.0001 compared to Htt-25Q (0 µM); P = 0.142, Htt-72Q (0.02 µM) vs Htt-72Q (0 
µM); P = 0.254, Htt-72Q (0.2 µM) vs Htt-72Q (0 µM); P = 0.781, Htt-72Q (2 µM) vs Htt-72Q (0 µM); n = 
12 wells per groups). 



















Figure S2.  Inhibition of DNMTs attenuates mutant Htt aggregates in primary cortical neurons 
(A) DIV 5 mouse primary cortical neurons were infected with Htt-72Q lentivirus and treated with 
decitabine or vehicle (DMSO). RNA was prepared at DIV 10 and subjected to qRT-PCR analysis for Htt-
72Q (human). β-actin and Hprt were used as reference genes. Decitabine did not decrease the levels of 
Htt-72Q mRNA compared to vehicle (ANOVA, n = 6 independent experiments).   
(B) DIV 5 cortical neurons were infected with Htt lentivirus and treated with decitabine (0.2 µM) or 
DMSO. Neurons were fixed at DIV 11-12 and subjected to indirect immunofluorescence with a specific 
mouse monoclonal Htt antibody EM48, which preferentially detects aggregated mutant protein. Nuclei 
were labeled with Hoechst 33342. Images were captured using an Operetta high-content imaging system 
(PerkinElmer) with a 20× objective lens. Bar, 100 µm. 
(C) EM48 immunofluorescence intensity in (B) was quantified using an ImageJ-based macro. Decitabine 
significantly decreased the levels of mutant Htt aggregates in Htt-72Q-expressing primary cortical 
neurons (ANOVA, *P < 0.0001 vs. Htt-72Q–DMSO, n = 18 wells from 6 independent experiments).  
(D) Cortical neurons transduced and processed as in (A) were directly harvested in SDS sample buffer at 
DIV 10 and subjected to immunoblotting with anti-Htt EM48 monoclonal antibody. Blot was reprobed with 
anti-β-actin antibody. Representative immunoblot from 3 independent experiments is shown. Decitabine 
could decrease the levels of aggregated high molecular weight mutant Htt in a stacking gel (*). 





















Figure S3. The effects of nucleoside analog DNMT inhibitors on mutant Htt-induced toxicity in 
primary neurons. 
 (A) DIV 5 cortical neurons transduced with lentivirus expressing Htt-72Q or Htt-25Q fragment were 
treated with the indicated drugs or DMSO (= 0 µM) and subjected to MTS assay at DIV 14. Decitabine, 
but not zebularine, increased the viability of mutant Htt-expressing neurons (ANOVA, *P < 0.0001 
compared to Htt-72Q (0 µM); no significant difference in survival between zebularine and vehicle-treated 
Htt-72Q neurons; n = 8-18 wells per group, 3 independent experiments). 
(B) Primary cortical neurons transduced and treated with 5-azacytidine were subjected to MTS assay as 
in (A). There was no significant difference in survival between 5-azacytidine- and vehicle-treated Htt-72Q 
neurons (ANOVA, n = 6-15 wells per group, 3 independent experiments).   
(C) Primary cortical neurons were transduced and treated as in (A) and subjected to neurofilament (NF) 
immunofluorescence. There was no significant difference in NF immunofluorescence intensity between 
5-azacytidine- and vehicle-treated Htt-72Q cortical neurons (ANOVA, n = 6-15 wells per group, 3 
independent experiments)  
(D) Primary striatal neurons transduced with Htt-25Q or Htt-72Q lentivirus at DIV 4 were treated with 5-
azacytidine or DMSO. Seven days later, neurons were subjected to NF immunofluorescence. There was 
no significant difference in NF immunofluorescence intensity between 5-azacytidine- and vehicle-treated 
Htt-72Q striatal neurons (ANOVA, n = 9-17 wells, 3 independent experiments).  










Figure S4. Knockdown of DNMT3A or DNMT1 did not decrease the expression of the other 
DNMTs. 
(A) DIV 5 cortical neurons were transduced with lentivirus expressing Dnmt3a shRNA (shDnmt3a-1 or -2) 
or control shRNA along with Htt-72Q virus; 5 days later, RNA was prepared and subjected to qRT-PCR 
analysis. Dnmt3a RNAi did not significantly reduce the levels of Dnmt1 mRNA in mutant Htt-expressing 
neurons, showing the specificity of these shRNAs (ANOVA, n = 3 independent experiments). 
(B) Cortical neurons were transduced with lentivirus expressing Dnmt1 shRNA (shDnmt1-1 or -2) or 
control shRNA along with Htt-72Q virus and processed as in (A). Dnmt1 RNAi did not decrease the 
levels of Dnmt3a mRNA in mutant Htt-expressing neurons, showing the specificity of these shRNAs 
(ANOVA, n = 3 independent experiments). 


























Figure S5. Analysis of CpG methylation status of Bdnf exon IV and VI regulatory regions in 
mutant Htt-expressing primary cortical neurons.   
(A) Primary cortical neurons were transduced with Htt-25Q or Htt-72Q at DIV 5. Five days later, genomic 
DNA was prepared and subjected to bisulfite DNA sequencing analysis on the 13 CpG sites in the 
regulatory region of Bdnf exon IV. The positions of CpG sites are indicated relative to the TSS.  Data are 
pooled from 7 independent experiments. Percentage of methylated cytosine residues was calculated and 
presented in Figure 4B. 
(B) Primary cortical neurons were transduced and processed for bisulfite DNA sequencing analysis on 
the 17 CpG sites in the regulatory region of Bdnf exon VI as in (A). Data are pooled from 3 independent 







Figure S6. In vitro stability of decitabine and FdCyd. 
(A) Decitabine (0.2 mM in saline) was first incubated at 37°C for indicated number of days in vitro and 
then added to the culture media at a final concentration 0.2 µM of DIV 5 primary cortical neurons 
transduced with Htt-25Q or Htt-72Q lentivirus. The neuroprotective activity of decitabine was tested using 
MTS assay at DIV 14. Decitabine lost its activity when tested after 11 days of incubation (ANOVA, *P < 
0.0001 compared to Htt-72Q plus vehicle, no difference between Htt-72Q plus vehicle vs Htt-72Q plus 
decitabine preincubated for 11 days, n = 9 wells, 3 independent experiments).  
(B) Similar experiments were performed with FdCyd as in (A). In contrast to decitabine, FdCyd 
preincubated for 11 or 45 days showed neuroprotective effects comparable to FdCyd with no 
preincubation (ANOVA, *P < 0.0001 compared to Htt-72Q plus vehicle, n = 9 wells, 3 independent 
experiments).  
Data are presented as mean + SEM.   
 
 
Table S1. List of compounds used in the epigenetic drug screen
1 CAY10433 HDAC inhibitor
2 Piceatannol Resveratrol analog
3 CAY10591 SIRT1 activator
4 EX-527 SIRT1 inhibitor
5 SAHA Calss I and II HDAC inhibitor
6 2-PCPA (hydrochloride) LSD1 inhibitor
7 3-amino Benzamide PARP inhibitor
8 SB 939 HDAC inhibitor 
9 PCI 34051 HDAC8 inhibitor
10 4-iodo-SAHA CalssI and II HDAC inhibitor (SAHA derivative)
11 Sirtinol SIRT inhibitor
12 C646 HAT p300 inhibitor
13 Tubastatin A (trifluoroacetate salt) HDAC6 inhibitor
14 Garcinol p300 and PCAF HAT inhibitor
15 Ellagic Acid Antioxidant; inhibitor of H3R17 methylation
16 Suberohydroxamic Acid (SBHA) HDAC inhibitor
17 Apicidin HDAC inhibitor
18 UNC0321 (trifluoroacetate salt) G9a HMTase inhibitor
19 (-)-Neplanocin A SAH hydrolase inhibitor (SAM-dependent MT inhibitor)
20 Cl-Amidine PAD4 deiminase inhibitor
21 F-Amidine (trifluoroacetate salt) PAD4 deiminase inhibitor
22 JGB1741 SIRT1 inhibitor
23 UNC0638 G9a HMTase inhibitor
24 Isoliquiritigenin Antioxidant, anti-inflammatory, antitumor activities
25 CCG-100602 Inhibitor of Rho pathway-mediated signaling and activation of serum response factor transcription
26 CAY10669 pCAF (p300/CREB-binding protein-associated factor) HAT inhibitor
27 Zebularine DNMT inhibitor
28 Delphinidin chloride p300/CBP HAT inhibitor
29 Suramin (sodium salt) SIRT1 inhibitor
30 Nicotinamide SIRT inhibitor
31 2,4-Pyridinedicarboxylic Acid Histone demethylase inhibitor
32 PFI-1 BET bromodomain inhibitor 
33 5-Azacytidine DNMT inhibitor
34 Decitabine DNMT inhibitor
35 (+)-JQ1 BET bromodomain inhibitor
36 (-)-JQ1 Negative control for (+)-JQ1
37 BSI-201 PARP1 inhibitor
38 1-Naphthoic Acid SIRT inhibitor
39 AG-014699 PARP-1 inhibitor
40 IOX1 inhibitor of 2-oxoglutarate oxygenases
41 MI-2 (hydrochloride) Inhibitor of the menin-MLL fusion protein interaction 
42 MI-nc (hydrochloride) Weak inhibitor of the menin-MLL fusion protein interaction; negative control for MI-2
43 Lomeguatrib O6-Methylguanine-DNA methyltransferase (MGMT) inhibitor
44 Daminozide Inhibitor of the human 2-oxoglutarate (JmjC) histone demethylases, KDM2A, PHF8, and KDM7A 
45 GSK-J1 (sodium salt) JMJD3 selective histone demethylase inhibitor
46 GSK-J2 (sodium salt) Poor JMJD3 inhibitor (negative control)
47 GSK-J4 (hydrochloride) JMJD3 selective histone demethylase inhibitor
48 GSK-J5 (hydrochloride) Weak JMJD3 demethylase inhibitor (inactive control)
49 Valproic Acid (sodium salt) HDAC inhibitor
50 Tenovin-1 p53 activator; SIRT1 and SIRT2 inhibitor
51 Tenovin-6 p53 activator; SIRT1, SIRT2, and SIRT3 inhibitor
52 Sodium Butyrate HDAC inhibitor
53 Anacardic Acid HAT (p300 and pCAF)  inhibitor; anti-inflammatory, anti-tumor, molluscicidal, and anti-microbial activity
54 AGK2 SIRT2 inhibitor
55 CAY10603 HDAC6 inhibitor
56 Chaetocin HMT inhibitor with selectivity for Lys9-HMTs (SU(VAR)3-9,  G9a, DIM5) 
57 Splitomicin Sir2p HDAC inhibitor
58 CBHA HDAC inhibitor,
59 M 344 HDAC inhibitor
60 Oxamflatin HDAC inhibitor
61 Salermide SIRT1 and SIRT2 inhibitor
62 Mirin Mre11-Rad50-Nbs1 (MRN) inhibitor
63 Pimelic Diphenylamide 106 Calss I HDAC inhibitor
64 (S)-HDAC-42 HDAC inhibitor
65 MS-275 HDAC (HDAC1) inhibitor
66 RG-108 DNMT inhibitor
67 2',3',5'-triacetyl-5-Azacytidine DNMT inhibitor
68 S-Adenosylhomocysteine (SAH) Product of SAM-dependent methylation of DNA, RNA, and histones and other proteins
69 UNC0224 G9a HMTase inhibitor
70 Chidamide HDAC inhibitor
71 3-Deazaneplanocin A S-adenosyl-L-homocysteine hydrolase inhibitor; EZH2 inhibitor
72 Sinefungin SET domain-containing methyltransferase inhibitor
73 N-Oxalylglycine Inhibitor of α-ketoglutarate-dependent enzymes  and prolyl hydroxylase domain-containing proteins PHD1 and PHD2
74 AMI-1 (sodium salt) PRMTs inhibitor
75 UNC1215 L3MBTL3 domain inhibitor
76 trans-Resveratrol Antioxidant, antiproliferative and anti-inflammatory activity, and cyclooxygenase-1 inhibitor
77 2,4-DPD HIF-PH inhibitor
78 DMOG HIF-PH inhibitor
79 Trichostatin A HDAC inhibitor
80 CAY10398 HDAC1 inhibitor
81 SGC0946 DOT1L inhibitor
82 EPZ5676 DOT1L inhibitor
83 EPZ6438 EZH2 inhibitor
84 GSK126 EZH2 inhibitor
1-80: Epigenetic Screening Library from Cayman Chemical (Item Number 11076)
81-84: Xcessbio Biosciences Inc.
Table S2.  List of primers used for experiments




Bdnf exon IX (protein coding) GACAAGGCAACTTGGCCTAC CGTGCTCAAAAGTGTCAGCC 
Bdnf exon I CCTGCATCTGTTGGGGAGAC GCCTTGTCCGTGGACGTTTA
Bdnf exon II CTAGCCACCGGGGTGGTGTAA CGCCTTCATGCAACCGAAGT 
Bdnf exon III GCTTCATTGAGCCCAGTTCC GCCTTGTCCGTGGACGTTTA
Bdnf exon IV CAGAGCAGCTGCCTTGATGTT GCCTTGTCCGTGGACGTTTA
Bdnf  exon VI TTGGGGCAGACGAGAAAGCGC AGGATGGTCATCACTCTTCTC
18s AGTCGGCATCGTTTATGGTC CGAAAGCATTTGCCAAGAAT
Hprt TTGACACTGGTAAAACAATGCAAAC GAGAGGTCCTTTTCACCAGCA








human HTT exon1 TCAACCTCCTCCACAGGCAC AGGCTCCTCAGCCACAGCT
(B) Primer sequences for bisulfite sequencing analysis
Genes Forward Reverse
Bdnf IV GTGAATTTGTTAGGATTGGAAGTGAAAATA CTAAACAAAAACTAAAAAATTTCATACTAACTC
Bdnf VI GGTAGGTATAGAGTTTTGGGTTTAAGTAG ACACTAAAATCAAACATTATTTAACTCTTC
(C) Primer sequences for MeDIP analysis
Genes Forward Reverse
Bdnf IV GCGCGGAATTCTGATTCTGGTA CTGCCTTGACGTGAGCTGTC
Gapdh CTCTGCTCCTCCCTGTTCC TCCCTAGACCCGTACAGTGC
(D) Primer sequences for ChIP analysis
Genes Forward Reverse
Bdnf IV CTTCTGTGTGCGTGAATTTGCT AGTCCACGAGAGGGCTCCA
